{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,3,31]],"date-time":"2022-03-31T03:42:13Z","timestamp":1648698133728},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2009,9,1]],"date-time":"2009-09-01T00:00:00Z","timestamp":1251763200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Orthop\u00e4de"],"published-print":{"date-parts":[[2009,9]]},"DOI":"10.1007\/s00132-009-1455-1","type":"journal-article","created":{"date-parts":[[2009,9,2]],"date-time":"2009-09-02T10:08:19Z","timestamp":1251886099000},"page":"835-842","source":"Crossref","is-referenced-by-count":0,"title":["Orthop\u00e4dische Patienten mit bzw. ohne Thrombophilie"],"prefix":"10.1007","volume":"38","author":[{"given":"J.F.","family":"Schenk","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B.","family":"Stephan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Kusma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Gro\u00df","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H.","family":"Eichler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2009,9,4]]},"reference":[{"key":"1455_CR1","unstructured":"Statistisches Bundesamt (2005) \u2013 Todesursachen 2005, S. 34 ICD-10: 126, 180, 170 \u2013 Version v. 12.03.2007 \u2013 http:\/\/www.destatis.de. Statistisches Bundesamt, Wiesbaden"},{"key":"1455_CR2","doi-asserted-by":"crossref","unstructured":"Cohen AT, Agnelli G, Anderson FA et al (2007) Venous thromboembolism (VTE) in Europe. The number of VTE events and associated morbidity and mortality- Thromb Haemost 98:756\u2013764","DOI":"10.1160\/TH07-03-0212"},{"key":"1455_CR3","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1001\/archinte.162.13.1451","volume":"162","author":"Strebel","year":"2002","unstructured":"Strebel N, Prins M, Agnelli G, B\u00fcller HR (2002) Preoperative or postoperative start of prophylaxis for venous thromboembolism with low molecular weight heparin in elective hip surgery. Arch Intern Med 162:1451\u20131456","journal-title":"Arch Intern Med"},{"key":"1455_CR4","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1055\/s-0038-1655355","volume":"18","author":"Krawczak","year":"1998","unstructured":"Krawczak M, Cooper DN (1998) The epidemiology of venous thrombosis. H\u00e4mostaseologie 18:1\u201313","journal-title":"H\u00e4mostaseologie"},{"key":"1455_CR5","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1159\/000022491","volume":"29","author":"Samama","year":"1999","unstructured":"Samama MM, Gerotziafas G, Conrad J et al (1999) Clinical aspects and laboratory problems in hereditary thrombophilia. Pathophysiol Haemost Thromb 29:76\u201399","journal-title":"Pathophysiol Haemost Thromb"},{"key":"1455_CR6","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1378\/chest.108.4_Supplement.312S","volume":"108","author":"Clagett","year":"1995","unstructured":"Clagett GP, Anderson FA Jr, Heit J et al (1995) Prevention of venous thromboembolism. Chest 108:312\u2013334","journal-title":"Chest"},{"key":"1455_CR7","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1378\/chest.08-0693","volume":"133","author":"Hirsh","year":"2008","unstructured":"Hirsh J, Guyatt G, Albers GW et al (2008) Executive summary: american college of chest physicians evidence-based clinical practice guidelines (8th edition). Chest 133:71\u2013109","journal-title":"Chest"},{"key":"1455_CR8","first-page":"2","volume":"3","author":"Encke","year":"2003","unstructured":"Encke A, Haas S, Krauspe R et al (2003) Station\u00e4re und ambulante Thromboembolie-Prophylaxe in der Chirurgie und der perioperativen Medizin \u2013 G97 Leitlinie. Mitteil Dtsch Gesellsch Chir 3:2\u20138","journal-title":"Mitteil Dtsch Gesellsch Chir"},{"key":"1455_CR9","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1024\/0301-1526.38.S76.1","volume":"38","author":"Encke","year":"2009","unstructured":"Encke A, Haas S, Sauerland S et al (2009) S3-Leitlinie \u2013 Prophylaxe der ven\u00f6sen Thromboembolie (VTE). Vasa 38(Suppl):1\u2013132","journal-title":"Vasa"},{"key":"1455_CR10","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1152\/ajplegacy.1916.41.2.250","volume":"41","author":"McLean","year":"1916","unstructured":"McLean J (1916) The thromboplastic action of cephalin. Am J Physiol 41:250\u2013257","journal-title":"Am J Physiol"},{"key":"1455_CR11","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1097\/00000658-193808000-00002","volume":"108","author":"Murray","year":"1938","unstructured":"Murray DWG, Best CH (1938) The use of heparin in thrombosis. Ann Surg 108:163\u2013173","journal-title":"Ann Surg"},{"key":"1455_CR12","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1016\/0006-291X(83)90550-8","volume":"116","author":"Choay","year":"1983","unstructured":"Choay J, Petitou M, Lormeau JC et al (1983) Structure activity relationships in heparin: a synthetic pentasaccharide with high affinity for antithrombin III and eleciting high anti factor Xa activity. Biochem Biophys Res Commun 116:492\u2013499","journal-title":"Biochem Biophys Res Commun"},{"key":"1455_CR13","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1016\/0006-291X(83)90550-8","volume":"116","author":"Choay","year":"1983","unstructured":"Choay J, Petitou M, Lormeau JC et al (1983) Structure activity relationships in heparin: a synthetic pentasaccharide with high affinity for antithrombin III and eleciting high anti factor Xa activity. Biochem Biophys Res Commun 116:492\u2013499","journal-title":"Biochem Biophys Res Commun"},{"key":"1455_CR14","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1073\/pnas.78.2.829","volume":"78","author":"Oosta","year":"1981","unstructured":"Oosta GM, Gardner WT, Beeder DL, Rosenberg RD (1981) Multiple functional domains of the heparin molecule. Proc Natl Acad Sci USA 78:829\u2013833","journal-title":"Proc Natl Acad Sci USA"},{"key":"1455_CR15","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1056\/NEJM198310203091605","volume":"309","author":"Leyvraz","year":"1983","unstructured":"Leyvraz P, Richard J, Bachmann F (1983) Adjusted versus fixed-dose subcutaneous heparin in the prevention of deep-vein thrombosis after total hip replacement. N Engl J Med 309:954\u2013958","journal-title":"N Engl J Med"},{"key":"1455_CR16","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/0049-3848(82)90116-5","volume":"28","author":"Thomas","year":"1982","unstructured":"Thomas DP, Merton RE (1982) A low molecular weight heparin compared with unfractionated heparin. Thromb Res 28:343\u2013345","journal-title":"Thromb Res"},{"key":"1455_CR17","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1055\/s-0038-1647623","volume":"60","author":"Barrowcliffe","year":"1988","unstructured":"Barrowcliffe TW, Curtis AD, Johnsson EA, Thomas DP (1988) An international standard for low molecular weight heparin. Thromb Haemost 60:1\u20137","journal-title":"Thromb Haemost"},{"key":"1455_CR18","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1378\/chest.114.5_Supplement.531S","volume":"114","author":"Clagett","year":"1998","unstructured":"Clagett GP, Anderson FA Jr, Geerts W et al (1998) Prevention of venous thromboembolism. Chest 114:531\u2013560","journal-title":"Chest"},{"key":"1455_CR19","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1378\/chest.124.6_suppl.349S","volume":"124","author":"Anderson","year":"2003","unstructured":"Anderson FA Jr, Hirsh J, White K, Fitzgerald RH Jr (2003) Temporal trends in prevention of venous thromboembolism following primary total hip or knee arthroplasty 1996\u20132001: findings from the Hip and Knee Registry. Chest 124:349\u2013356","journal-title":"Chest"},{"key":"1455_CR20","doi-asserted-by":"crossref","first-page":"1715","DOI":"10.1016\/S0140-6736(02)08652-X","volume":"359","author":"Lassen","year":"2002","unstructured":"Lassen MR, Bauer KA, Eriksson BI, Turpie AGG \u2013 EPHESUS (European Pentasaccharide Hip Elective Surgery Study) (2002) Postoperative Fondaparinux-Gabe im Vergleich mit pr\u00e4operativer Enoxaparin-Gabe zur Pr\u00e4vention ven\u00f6ser Thromboembolien nach elektiver H\u00fcftgelenksersatz-Operation: eine randomisierte Doppelblindstudie. Lancet 359:1715\u20131720","journal-title":"Lancet"},{"key":"1455_CR21","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1016\/S0140-6736(02)08648-8","volume":"359","author":"Turpie","year":"2000","unstructured":"Turpie AGG, Bauer KA, Eriksson BI, Lassen MR \u2013 PENTATHLON (Pentasaccharide in Total Hip Low Molecular Weight Heparin) (2000) Postoperative Fondaparinux-Gabe im Vergleich mit postoperativer Enoxaparin-Gabe zur Pr\u00e4vention ven\u00f6ser Thromboembolien nach elektiver H\u00fcftgelenksersatzoperation: eine randomisierte Doppelblindstudie. Lancet 359:1721\u20131726","journal-title":"Lancet"},{"key":"1455_CR22","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.1056\/NEJMoa011100","volume":"345","author":"Eriksson","year":"2001","unstructured":"Eriksson BI, Bauer KA, Lassen MR, Turpie AGG \u2013 PENTHIFRA (Pentasaccharide in Hip Fracture Surgery Study) (2001) Fondaparinux im Vergleich zu Enoxaparin zur Pr\u00e4vention einer ven\u00f6sen Thromboembolie nach H\u00fcftfrakturoperationen. N Engl J Med 345:1298\u20131304","journal-title":"N Engl J Med"},{"key":"1455_CR23","doi-asserted-by":"crossref","first-page":"1384","DOI":"10.1055\/s-0038-1649949","volume":"74","author":"Elalamy","year":"1995","unstructured":"Elalamy I, Lecrubier C, Potevin F et al (1995) Absence of in vitro cross-reaction of pentasaccharide with the plasma heparin- dependent factor of twenty-five patients with heparin-associated thrombocytopenia. Thromb Haemost 74:1384\u20131385","journal-title":"Thromb Haemost"},{"key":"1455_CR24","doi-asserted-by":"crossref","first-page":"1833","DOI":"10.1001\/archinte.162.16.1833","volume":"162","author":"Lassen","year":"2002","unstructured":"Lassen MR, Bauer KA, Eriksson BI, Lassen MR (2002) Fondaparinux vs enoxaparin for the prevention of venous thromboembolism in major orthopaedic surgery: A meta-analysis of 4 randomised double-blind studies. Arch Intern Med 162:1833\u20131840","journal-title":"Arch Intern Med"},{"key":"1455_CR25","doi-asserted-by":"crossref","first-page":"2349","DOI":"10.2146\/ajhp070178","volume":"64","author":"Shorr","year":"2007","unstructured":"Shorr AF, Kwong LM, Sarnes M et al (2007) Comparison of cost, effectiveness and safety of injectable anticoagulants used for thromboprophylaxis after orthopaedic surgery. Am J Health Syst Pharm 64:2349\u20132355","journal-title":"Am J Health Syst Pharm"},{"key":"1455_CR26","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1001\/archinte.163.11.1337","volume":"163","author":"Eriksson","year":"2002","unstructured":"Eriksson BI, Lassen MR (2002) PENTasaccharide in HIp-FRActure Surgery Plus investigators. Duration of prophylaxis against venous thromboembolism with fondaparinux after hip fracture surgery: A multicenter, randomized, placebo-controlled, double blind study. Arch Intern Med 163:1337\u20131342","journal-title":"Arch Intern Med"},{"key":"1455_CR27","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/S0140-6736(00)05249-1","volume":"358","author":"Eikelboom","year":"2001","unstructured":"Eikelboom JW, Quinlan DJ, Douketis JD (2001) Extended-duration prophylaxis against venous thromboembolism after total hip or knee replacement: a meta analysis of the randomised trials. Lancet 358:9\u201315","journal-title":"Lancet"},{"key":"1455_CR28","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1213\/01.ane.0000287677.95626.60","volume":"105","author":"Singelyn","year":"2007","unstructured":"Singelyn FJ, Verheyen CC, Piovella F et al (2007) The safety and efficacy of extended thromboprophylaxis with fondaparinux after major orthopaedic surgery of the lower limb with or without neuraxial or deep peripheral nerve catheter: the EXPERT Study. Anesth Analg 105:1540\u20131547","journal-title":"Anesth Analg"},{"key":"1455_CR29","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1038\/nbt1407","volume":"26","author":"Guerrini","year":"2008","unstructured":"Guerrini M, Beccati D, Shriver Z et al (2008) Oversulfated chondroitin sul fate is a contaminant in heparin associated with adverse clinical events. Nat Biotechnol 26:669\u2013675","journal-title":"Nat Biotechnol"},{"key":"1455_CR30","doi-asserted-by":"crossref","first-page":"2457","DOI":"10.1056\/NEJMoa0708078","volume":"358","author":"Schwarz","year":"2008","unstructured":"Schwarz LB (2008) Heparin comes clean. N Engl J Med 358:2457\u20132467","journal-title":"N Engl J Med"},{"key":"1455_CR31","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1378\/chest.08-0656","volume":"133","author":"Geerts","year":"2008","unstructured":"Geerts WH, Bergqvist D, Pineo GF et al (2008) Prevention of venous thromboembolism. American College of Chest Physicians \u2013 Based Clinical Practice Guidelines (8th Edition). Chest 133:381\u2013453","journal-title":"Chest"},{"key":"1455_CR32","doi-asserted-by":"crossref","first-page":"1458","DOI":"10.1001\/archinte.165.13.1458","volume":"165","author":"Tapson","year":"2005","unstructured":"Tapson VF, Hyers TM, Waldo AL et al (2005) Antithrombotic therapy practices in US hospitals in an era of practice guidelines. Arch Intern Med 165:1458\u20131464","journal-title":"Arch Intern Med"},{"key":"1455_CR33","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1016\/S0140-6736(07)61445-7","volume":"370","author":"Eriksson","year":"2007","unstructured":"Eriksson BI, Dahl OE, Rosencher N et al (2007) Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement: a randomised, double-blind, non-inferiority trial. Lancet 370:949\u2013956","journal-title":"Lancet"},{"key":"1455_CR34","doi-asserted-by":"crossref","first-page":"1354","DOI":"10.1592\/phco.28.11.1354","volume":"28","author":"Baetz","year":"2008","unstructured":"Baetz BE, Spinler SA (2008) Dabigatran etexilate: an oral direct thrombin inhibitor for prophylaxis and treatment of thromboembolic diseases. Pharmacotherapy 28:1354\u20131373","journal-title":"Pharmacotherapy"},{"key":"1455_CR35","doi-asserted-by":"crossref","first-page":"2765","DOI":"10.1056\/NEJMoa0800374","volume":"358","author":"Eriksson","year":"2008","unstructured":"Eriksson BI, Borris LC, Friedman RJ et al (2008) Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty. N Engl J Med 358:2765\u20132775","journal-title":"N Engl J Med"},{"key":"1455_CR36","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S0140-6736(08)60880-6","volume":"372","author":"Kakkar","year":"2008","unstructured":"Kakkar AK, Brenner B, Dahl OE et al (2008) Extended duration rivaroxaban versus short term enoxaparin for the prevention of venous thromboembolis after total hip arthroplasty: a double-blind, randomised controlled trial. Lancet 372:31\u201339","journal-title":"Lancet"},{"key":"1455_CR37","doi-asserted-by":"crossref","first-page":"2776","DOI":"10.1056\/NEJMoa076016","volume":"358","author":"Lassen","year":"2008","unstructured":"Lassen MR, Ageno W, Borris LC et al (2008) Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty. N Engl J Med 358:2776\u20132786","journal-title":"N Engl J Med"}],"container-title":["Der Orthop\u00e4de"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00132-009-1455-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00132-009-1455-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00132-009-1455-1","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,23]],"date-time":"2019-05-23T08:37:28Z","timestamp":1558600648000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00132-009-1455-1"}},"subtitle":["Diagnostik, Therapie und perioperative Einstellung"],"short-title":[],"issued":{"date-parts":[[2009,9]]},"references-count":37,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2009,9]]}},"alternative-id":["1455"],"URL":"https:\/\/doi.org\/10.1007\/s00132-009-1455-1","relation":{},"ISSN":["0085-4530","1433-0431"],"issn-type":[{"value":"0085-4530","type":"print"},{"value":"1433-0431","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,9]]}}}